Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Elizabeth Alqueza

PA-C

Elizabeth Alqueza, PA-C is a board certified Physician Associate at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She graduated from the University of Florida in 2004 with a Master of Physician Assistant Studies degree and subsequently completed the AASLD NP/PA Clinical Hepatology Fellowship. Elizabeth has worked in a variety of inpatient and outpatient settings with a strong commitment to patient care. Currently working at BIDMC Liver Center, Elizabeth has 5 years of dedicated experience in Hepatology. Her practice focuses primarily on steatotic liver disease, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Elizabeth is an active member of Gastroenterology and Hepatology Advanced Practice Providers.

play

Michelle Barnett

PA-C, MPAS, DFAAPA

Michelle Barnett is a highly experienced physician assistant specializing in patient-focused and evidence-based hepatology at Peak Gastroenterology Associates in Colorado Springs, Colorado. The most rewarding part of her position includes educating patients and collaborating with other GI advanced practice providers to enhance care for the growing MASLD/MASH population. She is now a subinvestigtor for hepatology clinical trials with Peak in Colorado Springs. With over 30 years in the GI and liver communities, she has held leadership roles, including serving as President of the Colorado Academy of Physician Assistants (CAPA) and receiving CAPA's Physician Assistant of the Year award. She is a national speaker and has given lectures for the AAPA, GHAPP and AANP. A graduate of Wichita State University and the University of Nebraska, Michelle has been recognized with the DFAAPA distinction and honors such as the Crohn’s and Colitis Foundation's IBD internship and the International Foundation for Gastrointestinal Disorders Ally Award. Passionate about holistic care, she incorporates lifestyle strategies like nutrition, yoga, and meditation into her practice. Outside of work, Michelle enjoys hiking, travel, musical theater, and supporting her favorite Colorado sports teams.

play

Sherona Bau

NP

Sherona Bau graduated from University of California, Los Angeles in 2008, with Master of Science in Nursing dual program specialized in Acute Care Nurse Practitioner and Clinical Nurse Specialist. In 2010, she has joined UCLA Pfleger Liver Institute and Asian Liver Cancer Center working as an outpatient Nurse Practitioner specializing in liver diseases including viral hepatitis, hepatobiliary diseases, alcohol related liver diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis, autoimmune liver diseases, and hepatocellular carcinoma. Since 2016, she has been a guest lecturer at UCLA School of Nursing for Master Entry Clinical Nurse (MECN) and MSN Adult/Gero Acute Care program. She is also a preceptor for Adult/Gero Acute Care Program. She participated in Hepatitis C Screening in the Community Churches to promote awareness of hepatitis C and the importance of treatment of hepatitis C. She also participates in Patient Symposium at UCLA to give a lecture to update care of the liver transplant patients. She is also a faculty of Gastroenterology Hepatology Advanced Practice Provider (GHAPP) since 2018 and a speaker for both GHAPP National meeting and Regional GHAPP in Los Angeles. Since 2013, she has published total 14 research papers and case report including the most recent three are Recommendations for the Management of MASH by Advanced Practice Providers in the US, Clinicians and Patients Confront Practical Issues in Wilson Disease, and Overview of chronic Hepatitis B management.

MASLD/MASH Learning Center

Latest News & Blogs

Will a "multivitamin" a day keep the "MASLD doctor" away?

November 2025

This commentary discusses the results of a study that assessed the relationship between homocysteine metabolism and histological severity of metabolic dysfunction-associated steatotic liver disease (MASLD), and applied a mathematical model to examine how replacement with different cofactors (pyridoxine, cobalamin, betaine, and folate) may affect homocysteine levels in patients with MASLD. It highlights the clinical implications of the study and examines the pathophysiological support behind the...

Read More arrow

TET3-overexpressing macrophages are a unifying pathogenic feature with therapeutic potential in chronic inflammatory diseases

November 2025

Increased activation of the NLRP3 inflammasome in immune cells, including macrophages, has been implicated in the pathogenesis of multiple chronic inflammatory diseases. Targeted depletion of macrophages has been explored as a cross-disease therapeutic strategy, but without subtype-specific markers, this strategy risks elimination of macrophages with homeostatic functions. In this study, Liu et al. identified a subpopulation of pathogenic macrophages, referred to as Toe-Macs, which are...

Read More arrow

Increased 1-deoxysphingolipids caused by an altered plasma alanine to serine ratio are associated with metabolic dysfunction-associated steatotic liver disease (MASLD)

November 2025

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (formerly Non-Alcoholic Fatty Liver Disease, NAFLD) encompasses a spectrum of metabolic disorders ranging from isolated steatosis to Metabolic Dysfunction-Associated Steatohepatitis (MASH), potentially progressing to cirrhosis and hepatocellular carcinoma (HCC). In this study, we investigated metabolic changes in MASLD by analysing plasma lipidomics and metabolomics profiles from 315 biopsy-characterized patients. We observed...

Read More arrow

Chemoprevention of hepatocellular carcinoma

October 2025

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and a leading cause of cancer-related deaths globally. Chronic liver disease (CLD), primarily due to viral hepatitis, alcohol use, and metabolic dysfunction-associated steatotic liver disease with steatohepatitis (MASLD/MASH), remains the major risk factor for HCC development. Chemoprevention, the use of medications or supplements to prevent or delay cancer, offers a compelling strategy to reduce HCC incidence,...

Read More arrow

Identification and Validation of Lipid Metabolism-Related Biomarkers GPD1 and CEBPD in Metabolic Dysfunction-Associated Steatohepatitis

October 2025

CONCLUSION: This study highlights the importance of GPD1 and CEBPD as potential diagnostic biomarkers and therapeutic targets for MASH, providing a theoretical and experimental foundation for improving early diagnostic strategies and developing interventions targeting inflammation and lipid metabolism dysregulation in metabolic liver disease.

Read More arrow

Cytochrome P450 as possible link between Mallory-Denk body formation in DDC-intoxicated mouse liver and human steatohepatitis

October 2025

Mallory-Denk bodies (MDBs) are hepatocytic inclusions in alcohol-related (ASH) and metabolic dysfunction-associated (MASH) steatohepatitis as well as in some other apparently etiologically different chronic human liver disorders. They are experimentally induced in mouse liver by chronic intoxication with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). Like in human diseases, mouse liver MDBs consist of stress proteins as major components indicating their relationship to chronic cellular stress....

Read More arrow

Cost-effective method for semi-quantitative analysis of soluble endoglin in biological samples after anti-endoglin monoclonal antibody treatment

October 2025

Soluble endoglin (sENG) is an important biomarker of several cardiometabolic and vascular disorders. The accurate measurement of biomarkers that are simultaneously targeted by therapeutic monoclonal antibodies (mAbs) in preclinical models is a significant challenge. Traditional enzyme-linked immunosorbent assays (ELISAs) often fail due to epitope blocking, while advanced techniques like mass spectrometry are more expensive and require specialized expertise. To address these limitations, we...

Read More arrow

Resmetirom, the first FDA-approved drug for MASH: From drug discovery and action mechanisms to clinical trials

October 2025

Metabolically-dysfunction-associated steatohepatitis (MASH) represents one spectrum of MASLD, affecting over 5.27% of adults globally. Until the approval of resmetirom, no pharmacological therapies were available for MASH. Resmetirom is prescribed for the management of non-cirrhotic MASH in adults with moderate to advanced hepatic fibrosis, specifically at Stages F2 to F3. This drug is uniquely transported via liver-targeted transporters and exerts its effects by closely replicating the...

Read More arrow

Translational framework linking perfluoroheptanoic acid (PFHpA) exposure to metabolic dysfunction associated steatotic liver disease in adolescents

October 2025

CONCLUSIONS: This study offers evidence implicating PFHpA, a short-chain unregulated PFAS congener, in MASLD development in adolescents, and highlights the critical role of protein dysregulation in disease pathogenesis. The molecular mechanisms identified here can inform the development of targeted prevention and treatment strategies.

Read More arrow

Analysis of factors affecting fibrosis reversal in patients with metabolic associated steatohepatitis based on magnetic resonance elastography

October 2025

Objective: To dynamically assess liver fibrosis using magnetic resonance elastography (MRE) and explore factors associated with fibrosis reversal in patients with metabolic dysfunction-associated steatohepatitis (MASH). Methods: This study included data from patients diagnosed with MASH by liver biopsy who underwent at least two MRE examinations. Patients were divided into a fibrosis reversal group and a non-reversal group according to whether MRE values decreased by 20% during follow-up....

Read More arrow

Sex and Race Disparities in Liver Listings and Transplants in the United States

October 2025

CONCLUSION: Our study findings call for public policies to address the rising burden from ALD and MASH and sex/ethnic disparities.

Read More arrow

AI portal tract detection and characterisation for a regional analysis of steatosis and inflammation in MASLD, MASH and AIH

October 2025

CONCLUSION: A new AI system for anatomical quantification of liver biopsy features measured variation in fat and inflammation across the lobule. It showed that inflammation burden was higher in AIH than MASLD/MASH, despite equivalent portal grades, providing objective support for histological scoring.

Read More arrow

Gut Microbiota Changes in Metabolic Dysfunction-Associated Steatohepatitis and Inflammatory Bowel Disease: Common Pathogenic Features

October 2025

Gut microbiota changes have emerged as central players in the pathogenesis of both metabolic dysfunction-associated steatohepatitis (MASH) and inflammatory bowel disease (IBD). Although these diseases affect distinct primary organs, they share converging mechanisms driven by dysbiosis, including loss of beneficial short-chain fatty acid-producing taxa such as Faecalibacterium prausnitzii and Roseburia, enrichment of pro-inflammatory Enterobacteriaceae, and disruption of bile acid and tryptophan...

Read More arrow

The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH

October 2025

Fibroblast growth factor 21 (FGF21) analogs have significant therapeutic potential in metabolic dysfunction-associated steatohepatitis (MASH) but limited body weight effects in patients with MASH. This study investigated the effect of combined treatment with the FGF21 analog zalfermin and the glucagon-like peptide-1 receptor agonist semaglutide on body weight and plasma and liver biochemistry and histology in a mouse model of MASH. Amylin liver nonalcoholic steatohepatitis diet-induced...

Read More arrow

Ultrasound Derived Fat Fraction (UDFF): An US Tool for Non-Invasive Diagnosis and Quantification of Hepatic Steatosis

October 2025

CONCLUSION: Although the correlation between UDFF and MR-PDFF is moderate to strong, this prospective study does not provide results as good as those of the few previous studies evaluating the UDFF technique. These results highlight the importance of standardizing techniques and measurements in order to position US steatosis quantification tools in the management of patients with MASLD and MASH.

Read More arrow

Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States

October 2025

CONCLUSION: In a real-world setting, very few patients achieved the treatment regimen associated with MASH resolution and improvements in fibrosis.

Read More arrow

The Bubble-Destruction Curve Obtained Using Contrast-Enhanced Ultrasound is Useful for Assessing Liver Fibrosis and Identifying At-risk MASH in Patients With MASLD

October 2025

CONCLUSION: The bubble-destruction curve derived from CEUS is a feasible and accurate approach for evaluating liver FIB in patients with MASLD. Furthermore, a composite model combining BDD derived from the bubble-destruction curve with AST and sex demonstrated good diagnostic accuracy for identifying at-risk MASH.

Read More arrow

Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

October 2025

Semaglutide has recently received conditional accelerated approval in the US for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with significant or advanced liver fibrosis (stage F2/F3). Phase 2 and 3 clinical trials show that subcutaneous semaglutide 2.4 mg/week leads to significant improvements in hepatic steatosis, disease activity, resolution of MASH and reduction in liver fibrosis. These benefits parallel weight loss and are accompanied by improved metabolic outcomes,...

Read More arrow

Prevalence and characteristics of metabolic dysfunction-associated steatohepatitis among pediatric patients in the MarketScan Databases

October 2025

INTRODUCTION: There are few epidemiologic studies of the prevalence of metabolic dysfunction-associated steatohepatitis (MASH) among pediatric populations.

Read More arrow

The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child-Pugh A Cirrhosis

October 2025

CONCLUSION: MASH cirrhosis is characterized by a broad spectrum of hepatic impairment and portal-systemic shunting. DSI, SHUNT%, and RISK ACE may provide early estimates of potential clinical benefit with resmetirom treatment. MAESTRO-NAFLD-1 was registered at ClinicalTrials.gov (NCT04197479).

Read More arrow